Phase II clinical trial of immunotherapy with WT1 peptide vaccination for pediatric hematological malignancies after allogeneic stem cell transplantation.

Phase II clinical trial of immunotherapy with WT1 peptide vaccination for pediatric hematological malignancies after allogeneic stem cell transplantation. - Phase II clinical trial of immunotherapy with WT1 peptide vaccination for pediatric hematological malignancies after allogeneic stem cell transplantation.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005319

Enrollment

Registered

2011-03-25

Start date

2008-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute lymphoid or myeloid leukemia, acute unclassified leukemia, malignant lymphoma

Interventions

Modified WT1 pepitide with montanide is subcutaneously injected weekly for 3months.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: See Japanese protocol or ask duresctly to us

Exclusion criteria

Exclusion criteria: Patients with severe complications.

Design outcomes

Primary

Measure	Time frame
Relapse free survival from the day of stem cell transplantation	—

Secondary

Measure	Time frame
Adverse events	—

Countries

Japan

Contacts

Public ContactYoshiko Hashii

Osaka University Pediatrics

areken@ped.med.osaka-u.ac.jp06-6879-3932

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026